The use of pooled human platelet lysate for isolation and ex vivo expansion of skeletal myoblasts for clinical use
Ranjitkar, Samir; Pinheiro, Alana Miranda; Boyer, Aaron; Zachar, Vladimir; Pennisi, Cristian Pablo Alejandro

Published in:
European Cells & Materials

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
? You may not further distribute the material or use it for any profit-making activity or commercial gain
? You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.
P397 The use of pooled human platelet lysate for isolation and ex vivo expansion of skeletal myoblasts for clinical use

Samir Ranjitkar¹, Alana Miranda Pinheiro¹, Aaron Boyer², Vladimir Zachar¹, Cristian Pablo Pennisi¹

¹Laboratory for Stem Cell Research, Aalborg University, Aalborg, Denmark, ²Cook MyoSite Inc, Pittsburgh, USA

Introduction: Ex vivo-expanded autologous myoblasts are being used in clinical trials for the treatment of various skeletal muscle conditions, including stress urinary incontinence caused by urethral sphincter damage. The use of fetal calf serum (FCS) as a growth media supplement in these procedures still raises various technical and ethical concerns. As an alternative to xenogeneic supplements, human platelet lysate (hPL) has recently gained increasing attention for ex vivo expansion of mesenchymal stem cells in clinical studies. However, little is known regarding the ability of hPL to support ex vivo expansion of skeletal myogenic precursors.

Aim: The aim of this study was to assess the performance of hPL for the isolation and expansion of human skeletal myoblasts in comparison to FCS.

Materials and methods: Skeletal myoblasts were isolated and expanded in a commercial medium formulation (MyoTonic, Cook Myosite) supplemented with either 10% FCS or 5% pooled hPL (Stemulate, Cook Regentec). Cells were assessed during multiple passage expansion by analysis of cell proliferation, cellular phenotype, and gene expression profiles. The ability of media to preserve the differentiation capacity of the cells was evaluated in cells from early and late passages by immunocytochemistry and qRT-PCR after induction with MyoTonic medium supplemented with 2% horse serum.

Results: Analysis of cell proliferation over five passages revealed that myoblasts cultured in hPL-supplemented medium displayed a significantly higher cumulative cell number over time, due to consistently larger growth rate. Cells grown in hPL media evidenced a lower activation during propagation, as revealed by a significantly lower transcription of the skeletal myogenic factors MYF5 and MYOD. The percentage of CD56 positive cells appeared to decrease over time with passaging irrespective of the media type, suggesting a progressive depletion of myogenic precursors over time. Nevertheless, the cells expanded in hPL evidenced a robust capacity for differentiation at early (P1) and late passages (P5), as demonstrated by the formation of myosin-rich mature myotubes displaying high levels of myogenin activation.

Conclusions: Our results suggest that the hPL supplemented medium supports isolation and efficient expansion of skeletal myoblasts while preserving their differentiation capacity. In perspective, hPL may represent an efficient alternative to FCS for the ex vivo expansion of myoblasts aimed for cell based therapies.